Owen Adams Catherine 4

What Happened Catherine Owen Adams, a director of Agios Pharmaceuticals (AGIO), had 1,976 restricted stock units (RSUs) convert into 1,976 shares on June 13, 2026. The Form 4 reports an exercise/conversion of a derivative (code M) showing the shares acquired at $0.00 and the derivative extinguished at $0.00, indicating these were vested/converted RSUs rather than a market purchase or sale. No cash was paid or received in this conversion.

Key Details

• Transaction date: June 13, 2026; Form 4 filed June 16, 2026 (timely).
• Reported amounts: 1,976 shares acquired at $0.00; 1,976 derivative units disposed at $0.00 (conversion of RSUs).
• Shares owned after the transaction: not specified in the provided excerpt (see the full Form 4 for total holdings).
• Footnotes: F1 = each RSU equals one share on conversion; F2 = RSUs were granted 6/13/2023 and vest in three equal annual installments beginning 6/13/2024, with vested shares delivered within three business days.
• No 10b5-1 plan, tax-withholding sale, or open-market sale is indicated in the provided data.

Context This is a routine, compensation-related RSU vesting/conversion rather than an insider buying or selling shares in the open market. Such conversions are common as restricted awards vest; they do not by themselves signal insider sentiment. The filing appears timely (filed three days after the transaction date). For complete ownership figures or any subsequent sales, consult the full Form 4 on the SEC EDGAR site.